Tag: Risk mitigation

According to the Institute for Safe Medication Practices (ISMP), intravenous (IV) oxytocin was added to its list of 'high-alert' medications in 2007, a designation for drugs with a heightened risk of causing significant patient harm when used in error. Understanding why **is oxytocin a high risk medication** is crucial for anyone involved in perinatal care.

In 2005, just months after its accelerated approval, the manufacturers of the promising multiple sclerosis drug Tysabri (natalizumab) voluntarily withdrew it from the market following the discovery of a rare but fatal brain infection. This decision was in direct response to why was Tysabri taken off the market and fundamentally reshaped drug development and safety protocols for high-efficacy treatments.